SEARCH

SEARCH BY CITATION

References

  • 1
    Müller U, Mosbech H, editors. EAACI position paper. Immunotherapy with Hymenoptera venoms. Allergy 1993; 48 Suppl 14:3746.
  • 2
    Mailing H-J, Weeke B, editors. EAACI position paper. Immunotherapy. Allergy 1993;48 Suppl 14:945.
  • 3
    Mailing H-J.: New ideas in allergen-specific immunotherapy. Am J Rhinol 1990;4:1558.
  • 4
    Dreborg S, Frew A, editors. Allergen standardization and skin tests. Allergy 1993:48 Suppl 14:4982.
  • 5
    van Metre TE, Adkinson NE Lichtenstein LM, et al.: A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:28897.
  • 6
    Hirsch SR, Kalbfleisch JH, Golbert TM, et al.: Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol 1981;68:13355.
  • 7
    Mctzger WJ, Dorminey HC, Richerson HB, Weiler JM, Donnelly A, Moran D.: Clinical and immunologic evaluation of glutaraldehyde-modified, tyrosine-absorbed short ragweed extract: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1981;68:4428.
  • 8
    Weyer A, Donat N, L'Heritier C, et al.: Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy 1981;36:30917.
  • 9
    Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R.: A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:4949.
  • 10
    Lee LK, Kniker WT, Campos T.: Aggressive coseasonal immunotherapy in mountain cedar pollen allergy. Arch Otolaryngol 1982;108:78794.
  • 11
    Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG.: Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70: 24860.
  • 12
    van Metre TE, Adkinson NE Amodio FJ, et al.: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:18193.
  • 13
    Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R.: A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72: 44853.
  • 14
    Blainey AD, Phillips MJ, Oilier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. Allergy 1984;39:5218.
  • 15
    Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R.: Asthma as a variable in a study of immunotherapy for allergic rhinitis. J Allergy Clin Immunol 1984;73:55760.
  • 16
    Ortolani C, Pastorello E, Moss RB, et al.: Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 28390.
  • 17
    Juniper EF, Roberts RS, Kennedy LK, et al.: Polyethylene glycol-modified ragweed pollen extract in rhinocon-junctivitis. J Allergy Clin Immunol 1985;75:57885.
  • 18
    Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R.: A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Immunol 1986;78:11804.
  • 19
    Meriney DK, Kothari H, Chinoy P, Grieco MH.: The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:348.
  • 20
    Bousquet J, Frank E, Soussana M, Hejjaoui A, Maasch HJ, Michel FB.: Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy. Int Arch Allergy Appl Immunol 1987;82:5502.
  • 21
    Bousquet J, Hejjaoui A, Skassa Brociek W, et al.: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with aller-goids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:5918.
  • 22
    Grammer LC, Shaughnessy MA, Bernhard MI, et al.: The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis. J Allergy Clin Immunol 1987;80:17783.
  • 23
    Bousquet J, Maarch H, Martinot B, Hejjaoui A, Wahl R, Michel FB.: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:43946.
  • 24
    Ewan PW, Alexander MM, Snape C, Ind PW.: Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:5018.
  • 25
    Bousquet J, Maasch HJ, Hejjaoui A, et al.: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:54656.
  • 26
    Corrado OJ, Pastorello E, Oilier S, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac°) in patients with perennial rhinitis. I. Clinical aspects. Allergy 1989;44:10815.
  • 27
    Fling JA, Ruff ME, Parker WA, et al.: Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:1019.
  • 28
    McHugh SM, Ewan PW.: Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy 1989;19:32734.
  • 29
    Parker WA, Whisman BA, Apaliski SJ, Reid MJ.: The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;84: 66777.
  • 30
    Bousquet J, Hejjaoui A, Soussana M, Michel F-B.: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:4907.
  • 31
    Horst M, Hejjaoui A, Horst V, Michel F-B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:46072.
  • 32
    Juniper EF. Kline, PA, Ramsdale EH, Hargreave, FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Polinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 1990;85:60611.
  • 33
    McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:52132.
  • 34
    Bousquel J, Becker WM, Hejjaoui A, et al.: Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:4353.
  • 35
    Iliopoulos O, Proud D, Franklin Adkinson N, et al.: Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergens: changes in inflam-matory mediators and cells. J Allergy Clin Immunol 1991;87:85566.
  • 36
    Litwin A, Pesce AJ, Fischer T, Michael M.: Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment. Clin Exp Allergy 1991;21:45765.
  • 37
    Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JMR.: Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergy 1991;46:33548.
  • 38
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR.: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:2659.
  • 39
    Brunet C, Bédard P-M, Lavoie A, Jobin M, Hébert J.: Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 1992;89:7686.
  • 40
    Pastorello EA, Pravettoni V, Incorvaia C, et al.: Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:28190.
  • 41
    Karmakar PR, Das A, Chatterjee BR. Placebo-controlled immunotherapy with Cocos nucifera pollen extract. Int Arch Allergy Immunol 1994;103:194201.
  • 42
    Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994;49:1321.
  • 43
    D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare° in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy 1995;25:14958.
  • 44
    Dolz I, Martínez-Cócera C, Bartolomé JM, Cimarra M.: A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489500.
  • 45
    Ariano R, Panzani RC Augeri G. Double-blind placebo controlled specific immunotherapy with mixed Cupres-saceae Taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol mmunopathol (Madr) 1997;25:239.
  • 46
    Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy 1997;52:6574.
  • 47
    Zenner HP, Baumgarten C.: Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:239.
  • 48
    Ortolani C, Pastorello E, Moss RB, et al.: Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 28390.
  • 49
    Pauli G, Bessot JC. Bigot H, et al. Clinical and immunologic evaluation of tyrosine-absorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984;74:52435.
  • 50
    Dreborg S, Agrell B, Foucard T, Kjellman N-IM, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. Allergy 1986;41: 13140.
  • 51
    Mailing H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:50719.
  • 52
    Reid MJ, Moss RB, Hsu Y-P, Kwasnicki JM, Commerford TM, Nelson BL.: Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590600.
  • 53
    Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L.: Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986;57:1739.
  • 54
    Bousquet J, Maasch H, Hejjaoui A. et al.: Double blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionatcd and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:54656.
  • 55
    Kuna P, Alam R. Kumanska B, Rozniecki J.: The effect of preseasonal immunowerapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989;83:81624.
  • 56
    Bousquet J, Hejjaoui A, Soussana M, Michel FB.: Double blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:4907.
  • 57
    Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint-Remy J-MR. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes J Clin Invest 1990;85:102435.
  • 58
    Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quirós A.: Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994:93:55666.
  • 59
    Creticos PS, Reed CE, Norman PS, et al.: Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334: 5016.
  • 60
    Pickler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:27483.
  • 61
    Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ.: Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997;27:8607.
  • 62
    Olsen OT, Larsen KR, Jacobsen L, Svendsen UG.: A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:8539.
  • 63
    Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in catinduced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74:2309.
  • 64
    Valovirta E, Koivilcko A, Vanto T, Viander M, Ingeman L.: Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984;53:858.
  • 65
    Bousquet J, Calvayrac P, Guérin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76:73444.
  • 66
    Sundin B, Lilja G, Graff-Lonnevig V, et al.: Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:47887.
  • 67
    van Metre TE, Marsh DG, Adkinson NF, et al.: Immunotherapy for cat asthma. J Allergy Clin Immunol 1988;82:105568.
  • 68
    Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al.: Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989;63:12735.
  • 69
    Haugaard L, Dahl R.: Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992;47:24954.
  • 70
    van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992;5:31822.
  • 71
    Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL.: Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995;50:92530.
  • 72
    Adkinson FN, Eggleston PA, Eney D, et al.: A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:32431.
  • 73
    Grant JA, Nicodemus CF, Findlay SR, et al.: Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995;95:92332.
  • 74
    Bronsky WA, Dockhorn RJ, Meltzer EO, et al.: Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:91521.
  • 75
    Scadding GK, Lund VJ, Jacques LA, Richards DH.: A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:73743.
  • 76
    Haahtela T, Järvinen M, Kava T, et al. Comparison of β2 pyagonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:38892.
  • 77
    Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C.: Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992;5:94552.
  • 78
    Chervinsky P, van As A, Bronsky EA, et al.: Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:67683.
  • 79
    Ayres JG, Bateman ED, Lundbäck B, Harris TAJ.: High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8:57986.
  • 80
    König P, Schaffer J.: The effect of drug therapy on long-term outcome of childhood asthma: a possible preview of the international guidelines. J Allergy Clin Immunol 1996;98:110311.
  • 81
    Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE.: Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993;92:615.
  • 82
    Stewart GE II, Lockey RF.: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90: 56778.
  • 83
    Hejjaoui J, Ferrando R, Dhivert H, Michel FB, Bousquet J.: Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89:92533.
  • 84
    Tabar Al García BE, Rodríaguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts Allergy 1993;48:4503.